Show simple item record

Authordc.contributor.authorUribe, Francisca 
Authordc.contributor.authorAlister, Juan Pablo 
Authordc.contributor.authorZaror, Carlos 
Authordc.contributor.authorOlate, Sergio 
Authordc.contributor.authorFariña, Rodrigo 
Admission datedc.date.accessioned2020-05-28T22:26:50Z
Available datedc.date.available2020-05-28T22:26:50Z
Publication datedc.date.issued2020
Cita de ítemdc.identifier.citationThe Cleft Palate-Craniofacial Journal 2020, Vol. 57(5) 589-598es_ES
Identifierdc.identifier.other10.1177/1055665619886142
Identifierdc.identifier.urihttp://repositorio.uchile.cl/handle/2250/175072
Abstractdc.description.abstractObjective: This study aimed to review the existing evidence regarding reconstruction of the alveolar cleft using recombinant human bone morphogenetic protein-2 (rhBMP-2) in terms of bone volume and bone height. Design: Systematic review and meta-analysis. Patients-Participants: A systematic search was done. Randomized and nonrandomized clinical trials, where rhBMP-2 was used in the reconstruction of human alveolar cleft were included. Interventions: Reconstruction of alveolar cleft with rhBMP-2. Main Outcome Measures: Average bone volume formation and average bone height formation in the alveolar cleft. Mean difference was calculated and pooled by meta-analysis. Results: Of 709 identified articles, 5 studies met the inclusion criteria. The average bone volume formation was higher in the rhBMP-2 group than in the control group (61.11% vs 59.12%). The average bone height formation was higher in the control group compared to the rhBMP-2 group (75.4% vs 61.5%). The risk of bias in the selected articles was high. The meta-analysis showed that rhBMP-2 treatment may benefit bone formation compared to iliac crest graft (low certainty evidence; mean difference: -208.76; 95% confidence interval: -253.59 to -163.93; -I-2 = 0%). Conclusions: The results obtained in primary articles are promising but have a high risk of bias and have low quality of evidence; therefore, it is necessary to conduct controlled clinical trials with a greater number of patients to recommend the use of rhBMP-2 in the treatment of the alveolar cleft. PROSPERO registration number: CRD42018077741.es_ES
Patrocinadordc.description.sponsorshipComision Nacional de Investigacion Cientifica y Tecnologica (CONICYT) CONICYT-PCHA/doctoradonacional/2015-21150752es_ES
Lenguagedc.language.isoenes_ES
Publisherdc.publisherAlliance Communications Group Division Allenes_ES
Type of licensedc.rightsAttribution-NonCommercial-NoDerivs 3.0 Chile*
Link to Licensedc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/cl/*
Sourcedc.sourceThe Cleft Palate-Craniofacial Journales_ES
Keywordsdc.subjectAlveolar cleftes_ES
Keywordsdc.subjectAlveolar bone graftinges_ES
Keywordsdc.subjectRhBMP-2es_ES
Keywordsdc.subjectBone morphogenetic proteines_ES
Keywordsdc.subjectSystematic reviewes_ES
Keywordsdc.subjectMeta-analysises_ES
Títulodc.titleAlveolar Cleft Reconstruction Using Morphogenetic Protein (rhBMP-2): A Systematic Review and Meta-Analysises_ES
Document typedc.typeArtículo de revistaes_ES
Catalogueruchile.catalogadorcrbes_ES
Indexationuchile.indexArtículo de publicación ISIes_ES


Files in this item

Icon

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 Chile
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 Chile